CN1449793A - Anti-cancer medicine and preparation process thereof - Google Patents
Anti-cancer medicine and preparation process thereof Download PDFInfo
- Publication number
- CN1449793A CN1449793A CN 03113423 CN03113423A CN1449793A CN 1449793 A CN1449793 A CN 1449793A CN 03113423 CN03113423 CN 03113423 CN 03113423 A CN03113423 A CN 03113423A CN 1449793 A CN1449793 A CN 1449793A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- agrimony
- cancer therapy
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an anticancer medicine. It is prepared from agrimony (agrimonia pilosa) and bearded scutellaria or added with ethyl alcohol and water extracts of sargassum and ganoderma, mixed them with auxilairy material and adopting conventional process of the Chinese medicine to obtain said invented product. Said anticancer medicine has the effect of supplementing vacuity, strengthening stomach, removing toxic material and softening hardness, and has good anticancer effect and broad anticance spectrum and has no clear toxic side reaction.
Description
One, technical field:
The present invention relates to a kind of cancer therapy drug, specifically is cancer therapy drug of making of raw material and preparation method thereof with the Chinese herbal medicine.
Two, background technology:
Cancer is the formidable enemy of harm humans health.China annual New Development cases of cancer 1,600,000 people die from cancer 300,000 people every year.Rise year by year because of the dead number of cancer in the whole nation.
Still there are not the most of cancer patients of effective cured substance at present.Though chemotherapeutics has certain curative effect to cancer, toxic and side effects big (Han Shaoting. newly organized antitumor drug handbook. Jinan: Shandong science tech publishing house, 1995.27).Chinese patent medicine is generally lower to the curative effect of cancer, as to join the lotus capsule be that Tonghua City biochemical-pharmaceutical factory, 3.5%[Jilin produces to the cancer remission rate of lung gastric cancer, authentication code is defended the accurate word Z-58 of medicine number for (94)], curative effect also undesirable (Sun Ding people etc. homemade new drug application manual. Beijing: People's Medical Officer Press, 2000.740).
Three, summary of the invention:
1, goal of the invention:
The purpose of this invention is to provide a kind of tonify deficiency be good for the stomach, detoxify remarkable efficacy of softening the hard mass that has, anticancer effect is good and do not have the cancer therapy drug of obvious toxicity, and another goal of the invention provides the preparation method of this cancer therapy drug.
2, technical scheme:
The objective of the invention is to realize by following technical scheme:
A kind of cancer therapy drug, it is that the crude drug that Herba Scutellariae Barbatae is 2～3 parts is made by 2～3 parts of Herba Agrimoniaes (Agrimony) (weight portion, down together).
Can also add one to two flavor accessory drugs in the crude drug of above-mentioned cancer therapy drug, i.e. 1～2 part of Sargassum simply also can add simply 1～2 part of Ganoderma again, increases simply that Sargassum has the softening the hard mass effect that strengthens medicine, and increasing simply again, Ganoderma has the tonify deficiency effect that strengthens medicine.Contain polysaccharide component in Sargassum and the Ganoderma simultaneously, also have antitumaous effect.
The method for making of above-mentioned cancer therapy drug is as follows:
1, get 2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes, add 10～30 parts of 80%～95% ethanol, flooded after 24 hours reflux, extract, 2～3 hours, the leaching alcohol extract, standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7～10 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum A.
2, get 2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes, 1～2 part of Sargassum, add 10～30 parts of 80%～95% ethanol, flooded after 24 hours reflux, extract, 2～3 hours, the leaching alcohol extract, standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7～10 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum B.
3, get 2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes, 1～2 part of Sargassum, 1～2 part of Ganoderma, add 10～30 parts of 80%～95% ethanol, flooded after 24 hours reflux, extract, 2～3 hours, the leaching alcohol extract, standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7～10 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum C.
Above-mentioned extractum A, B or C are added dextrin with 1: 1 ratio respectively mix,, pulverize, cross sieve No. 3, add an amount of 70% alcohol granulation at≤60 ℃ of drying under reduced pressure, cold drying, granulate is packed, and promptly gets oral granule electuary A, B or the C of cancer therapy drug of the present invention.
3, beneficial effect:
An important feature of medicine of the present invention is that anticancer effect is good.The present invention shows that through clinical and animal experiment study following advantage is arranged:
1. has tonify deficiency be good for the stomach, the detoxify remarkable efficacy of softening the hard mass.
2. anticancer effect is good.Its cancer remission rate to terminal cancer is 8.0%, and the cancer coefficient of stabilization is 82.0%.
3. anticancer spectrum is wide.It all has excellent curative to pulmonary carcinoma, gastric cancer, the esophageal carcinoma, hepatocarcinoma etc.
4. has the effect that significantly improves cancer patient's life quality.
5. there is not obvious toxicity.
Four, the specific embodiment
The method for making of embodiment 1 cancer therapy drug
Get 2 parts of Herba Agrimoniaes (Agrimony), 2 parts of Herba Scutellariae Barbataes, 1 part of Sargassum, 1 part of Ganoderma, add 10 parts of 80% ethanol, flooded after 24 hours reflux, extract, 2 hours, the leaching alcohol extract, standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum C.Extractum C is added dextrin in 1: 1 ratio mix,, pulverize, cross sieve No. 3, add an amount of 70% alcohol granulation at≤60 ℃ of drying under reduced pressure, cold drying, granulate is packed, and promptly gets the oral granule electuary C of cancer therapy drug of the present invention.
Embodiment 2
Get 3 parts of Herba Agrimoniaes (Agrimony), 3 parts of Herba Scutellariae Barbataes, 2 parts of Sargassums, 2 parts of Ganodermas, make the oral granule electuary C of cancer therapy drug by the step of embodiment 1.
Embodiment 3
Get 3 parts of Herba Agrimoniaes (Agrimony), 2 parts of Herba Scutellariae Barbataes, make the oral granule electuary A of cancer therapy drug by the step of embodiment 1.
The clinical effectiveness of the oral granule electuary C treatment cancer of embodiment 4 cancer therapy drugs
4.1 clinical data, Therapeutic Method and efficacy assessment standard:
The 150 routine terminal cancer of making a definite diagnosis through pathology (pulmonary carcinoma, gastric cancer, the esophageal carcinoma etc.) are divided into treatment group 100 example and matched group 50 examples at random, two groups of treatments are preceding at aspects such as sex, age, cancer kind, clinical stages, life qualities, all do not have significant difference (P＞0.05), have comparability.The treatment group adopts anticancer drug therapy, each 20g, every day 3 times; Matched group adopts chemotherapy regimen treatments such as EP, MOP, ELF, FP.The efficacy evaluation of cancer is a foundation with WHO cancer evaluation criteria.The life quality standard adopts the Kamofsky standards of grading.
4.2 therapeutic outcome:
4.2.1 cancer is alleviated situation:
Treatment group cancer remission rate (CR+PR) is 8.0%, and matched group cancer remission rate (CR+PR) is 12.0%, two group does not relatively have significant difference (P＞0.05); Treatment group cancer coefficient of stabilization is 82.0%, and matched group cancer coefficient of stabilization is 62.0%, two group relatively highly significant difference (P＜0.0), illustrates that anticarcinogen is being better than chemotherapeutics aspect the control cancer development.
Cancer is alleviated situation
Alleviate part fully and alleviate stable total remission rate (%) the cancer coefficient of stabilization (%) that worsens
The example number
(CR) (PR) (SD) (PD) (CR+PR) (CR+PR+SD) treatment organize 100 35 74 18 8.0%
*82.0%
*Matched group 50 06 25 19 12.0% 62.0%
Treatment group and matched group compare: * X
2=0.6308 P＞0.05; * X
2=7.1753 P＜0.01
4.2.2 life quality curative effect:
Treatment group life quality climbing is 28.0%, and rate of descent is 10.0%; Matched group life quality climbing is 6.0%, and rate of descent is 28.0%, two group relatively highly significant difference (P＜0.01), illustrates that anticarcinogen is being better than chemotherapeutics aspect the raising patient with advanced cancer life quality.
Life quality efficacy analysis (example)
Example number rising (%) stable (%) decline (%)
Treatment organizes 100 28 (28.0) 62 (62.0) 10 (10.0)
Matched group 50 3 (6.0) 33 (66.0) 14 (28.0)
Treatment group and matched group compare: X
2=14.6398 P＜0.01
Embodiment 5 anticancer animal experiment studies:
5.1 the oral granule electuary A of cancer therapy drug is to the inhibitory action of rat liver cancer H22:
Experiment material: Kunming mouse, male and female half and half, body weight 18g～22g, Jiangsu Province Medicine Primary Institute animal housing provides, the quality certification number: No. 96011, Soviet Union's kinoplaszm.Tumor strain: hepatocarcinoma H22, the institute of materia medica, Shanghai provides.Get the hepatocarcinoma H22 ascites of inoculation after 7 days, become the H22 suspension standby by 1: 3 dilution proportion with normal saline.Medicine: 5-fluorouracil (5-FU), lot number: 9504011, Shanghai Xudong Hipu Medicine Co., Ltd produces, and is mixed with 4mg/ml concentration with normal saline.Take by weighing quantitative anticarcinogen electuary A, grind with distilled water and be mixed with 0.16g/ml, 0.08g/ml, three concentration liquids of 0.04g/ml.
Experimental technique: it is subcutaneous that hepatocarcinoma H22 suspension is expelled to mice right fore armpit with 0.2ml/ amount only, after 24 hours mice is divided at random matched group, 5-FU group, three dosage of anticarcinogen electuary A (4g/kg, 2g/kg, 1g/kg) group, every group of 10 mices.Anticarcinogen electuary A organizes and gives mice ig administration 1 time every day, each 0.5ml/20g body weight; The 5-FU group is lumbar injection, every day 1 time, each 0.2ml/20g body weight; Matched group ig equivalent distilled water, each organizes equal successive administration 7 days.The mice drug withdrawal was weighed after 1 day, drew neck to put to death, and strip the tumor piece and weigh, by " tumour inhibiting rate=(1-T/C) * 100% " formula calculating tumour inhibiting rate.
Experimental result: the tumor bulk-growth that anticarcinogen electuary A1g/kg, 2g/kg, 4g/kg change entity to rat liver cancer H22 ascites has obvious inhibitory action.Wherein the anticarcinogen electuary A4g/kg tumour inhibiting rate of organizing continuous two batches of experiments is respectively 63%, 46%, and (P＜0.01=, illustrating that anticarcinogen electuary A has rat liver cancer H22 suppresses or lethal effect with matched group significant differences more all.
Anticarcinogen electuary A is to tumor-bearing mice (H
22) influence of tumor bulk-growth
Dosage number of animals the weight of animals (g) tumor body weight (g) tumour inhibiting rate
Group
(g/kg * d) (N) (beginning/end) (X ± SD) (%)
Matched group 10 20,/25 1.46 ± 0.41
5-FU 0.04 * 7 10 21,/25 0.65 ± 0.14**, 55 anticarcinogen electuary A, 4 * 7 10 20/26.5 0.78 ± 0.20** 46
2×7 10 21/27.5 0.87±0.35** 40
1×7 10 22/28 1.00±0.31* 31
Matched group 10 21,/26 1.60 ± 0.49
5-FU 0.04 * 7 10 21,/25 0.28 ± 0.16**, 82 anticarcinogen electuary A, 4 * 7 10 20/26.5 0.60 ± 0.36** 63
2×7 10 21/27.5 0.84±0.41** 47
1×7 10 22/28 0.93±0.58** 42
* compare with matched group P＜0.05 * * P＜0.01
5.2 the oral granule electuary C of cancer therapy drug is to the inhibitory action of mice transplanted tumor S180:
Experiment material: Kunming mouse, male and female half and half, body weight 18g～22g, Jiangsu Province Medicine Primary Institute animal housing provides, the quality certification number: No. 96011, Soviet Union's kinoplaszm.Tumor strain: S180, the institute of materia medica, Shanghai provides.The preparation of S180 oncocyte homogenate suspension: select 7～10 days tumor growth of inoculation vigorous and do not have diabrosis, the animal situation is tumor source animal preferably, and the tumor piece is got in the cervical vertebra dislocation under the sterile working, and 1 tumor piece adds 3 normal saline, and to be mixed with homogenate standby.Medicine: cyclophosphamide, lot number: 960210, Hualian Pharmaceutical Co., Shanghai produces, and is mixed with the 2mg/ml concentration liquid with normal saline.Take by weighing quantitative anticarcinogen electuary C, grind with distilled water and be mixed with 0.16g/ml, 0.08g/ml, three concentration liquids of 0.04g/ml.
Experimental technique: it is subcutaneous that the S180 oncocyte homogenate suspension of preparation is inoculated in mice right fore armpit with 0.2ml/ amount only, after 24 hours vaccinated mice is divided at random matched group, cyclophosphamide group, three dosage of anticarcinogen (4g/kg, 2g/kg, 1g/kg) group, every group of 10 mices.Give anticarcinogen group every day mice ig administration 1 time, each 0.5ml/20g body weight; The cyclophosphamide group is a lumbar injection, every day 1 time, each 0.2ml/20g body weight; Matched group ig equivalent distilled water, each organizes equal successive administration 7 days.The mice drug withdrawal was weighed after 1 day, drew neck to put to death, and strip the tumor piece and weigh, by " tumour inhibiting rate=(1-T/C) * 100% " formula calculating tumour inhibiting rate.
Experimental result: anticarcinogen electuary C2g/kg, 4g/kg have obvious inhibitory action to the tumor bulk-growth of mouse transplanted sarcoma S180.Wherein the anticarcinogen electuary C4g/kg tumour inhibiting rate of organizing continuous two batches of experiments is respectively 40%, 41%, and (P＜0.01=, illustrating that anticarcinogen electuary C has mouse transplanted sarcoma S180 suppresses or lethal effect with matched group significant differences more all.
Anticarcinogen electuary C is to tumor-bearing mice (S
180) influence of tumor bulk-growth
Dosage number of animals the weight of animals (g) tumor body weight (g) tumour inhibiting rate
Group
(g/kg * d) (N) (beginning/end) ((%) matched group 10 21,/26 1.07 ± 0.21 cyclophosphamide 0.02 * 7 10 21/24.5 0.27 ± 0.20**, 75 anticarcinogen electuary C, the 4 * 7 10 22/27.5 0.63 ± 0.26** 41 of X ± SD)
2×7 10 21/26 0.79±0.24* 26
1 * 7 10 20.5/28 0.83 ± 0.16*, 22 matched groups, 10 21/24.4 1.25 ± 0.42 cyclophosphamide 0.02 * 7 10 21/26.6 0.45 ± 0.31**, 64 anticarcinogen electuary C, 4 * 7 10 21,/24 0.75 ± 0.34** 40
2×7 10 21/25 0.90±0.28* 28
1×7 10 21/26 1.02±0.37 18
* compare with matched group p＜0.05 * * p＜0.01
Claims (5)
1, a kind of cancer therapy drug is characterized in that it is made by following bulk drugs and weight proportion:
2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes.
2, cancer therapy drug according to claim 1 is characterized in that can adding accessory drugs Sargassum simply in the above-mentioned raw materials medicine, promptly Herba Agrimoniae (Agrimony) is 2～3 parts, 2～3 parts of Herba Scutellariae Barbataes, and 1～2 part of Sargassum is made.
3, cancer therapy drug according to claim 1 is characterized in that can also adding accessory drugs Ganoderma simply again in the above-mentioned raw materials medicine, promptly Herba Agrimoniae (Agrimony) is 2～3 parts, 2～3 parts of Herba Scutellariae Barbataes, and 1～2 part of Sargassum, 1～2 part of Ganoderma is made.
4, a kind of method for preparing claim 1,2 or 3 described cancer therapy drugs is characterized in that its preparation process is:
1. get 2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes, add ethanol, flood reflux, extract, after 24 hours, the leaching alcohol extract, standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7～10 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum A.
2. get 2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes, 1～2 part of Sargassum, add ethanol, flood reflux, extract, after 24 hours, the leaching alcohol extract, standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7～10 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum B.
3. get 2～3 parts of Herba Agrimoniaes (Agrimony), 2～3 parts of Herba Scutellariae Barbataes, 1～2 part of Sargassum, 1～2 part of Ganoderma adds ethanol, floods reflux, extract, after 24 hours, and the leaching alcohol extract is standby behind the reduced-pressure backflow ethanol; Medicinal residues decoct with water 2 times again, add 7～10 times of amounts of water at every turn, decoct 1 hour after-filtration taking liquid.Alcohol extract is mixed with decoction liquor, and concentrating under reduced pressure gets extractum C.
4. extractum A, B and C are added dextrin with 1: 1 ratio respectively and mix,, pulverize, cross sieve No. 3, add an amount of 70% alcohol granulation at≤60 ℃ of drying under reduced pressure, cold drying, granulate is packed, and promptly gets oral granule electuary A, B and the C of cancer therapy drug of the present invention.
5, the preparation method of cancer therapy drug according to claim 4 is characterized in that concentration of alcohol is 10～30 parts of 80%～95% consumptions (weight portion), reflux extracting time 2～3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113423 CN1449793A (en) | 2003-05-12 | 2003-05-12 | Anti-cancer medicine and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113423 CN1449793A (en) | 2003-05-12 | 2003-05-12 | Anti-cancer medicine and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1449793A true CN1449793A (en) | 2003-10-22 |
Family
ID=28684064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03113423 Pending CN1449793A (en) | 2003-05-12 | 2003-05-12 | Anti-cancer medicine and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1449793A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168555A (en) * | 2015-09-28 | 2015-12-23 | 张光荣 | Preparation for treating cerebral cancer and preparation method of preparation |
| CN108355017A (en) * | 2018-04-02 | 2018-08-03 | 刘新江 | Celestial spirit is returned sun and is dissipated |
-
2003
- 2003-05-12 CN CN 03113423 patent/CN1449793A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168555A (en) * | 2015-09-28 | 2015-12-23 | 张光荣 | Preparation for treating cerebral cancer and preparation method of preparation |
| CN108355017A (en) * | 2018-04-02 | 2018-08-03 | 刘新江 | Celestial spirit is returned sun and is dissipated |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101559095B (en) | Veterinary compound acanthopanax granules with immunopotentiation and preparation method thereof | |
| CN105816430A (en) | Preparation method of radix tetrastigme polysaccharide particle with antitumor function | |
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN104857435B (en) | A kind of Traditional Chinese medicine compound composition with antitumor activity and its preparation method and application | |
| CN1686404A (en) | Dangshen astragalus composition for regulating immunity and its preparation method | |
| CN1792244A (en) | Anti-fatigue and health-care food, and its prepn. method | |
| CN1449793A (en) | Anti-cancer medicine and preparation process thereof | |
| CN1281613C (en) | Chinese medicine gelsmium elegans total alkaloid for anticancer and analgesia, and medicinal composition containing it and preparing method thereof | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN108186794A (en) | A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application | |
| CN104825783B (en) | Chinese medicine composition with antitumor activity and its preparation method and application | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN106074643B (en) | Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN104998003B (en) | A kind of preparation method of Chinese medicine composition | |
| CN100349585C (en) | Dampness dispersing, cancer resisting medicine, its preparation method and its application in the process for preparing anticancer medicine | |
| CN1241555C (en) | Elemene fatty emulsion injection and preparing method thereof | |
| CN1121237C (en) | Health-care products for regulating immunological function and delaying senility | |
| CN104840746B (en) | A kind of Chinese medicine composition with anti-lung cancer activity and its preparation method and application | |
| CN101066291A (en) | Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN1297297C (en) | Traditional Chinese medicine composition, its preparation method and application for preparing medicine to treat cancer | |
| CN1823884A (en) | Preparation method of aidi injection agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |